{
  "ticker": "ARGX",
  "company_name": "argenx SE",
  "success": true,
  "trials": [
    {
      "nct_id": "NCT06307613",
      "title": "A Study of Efgartigimod PH20 SC Given by Prefilled Syringe in Adults With Thyroid Eye Disease",
      "status": "ACTIVE_NOT_RECRUITING",
      "phase": "PHASE3",
      "condition": "Thyroid Eye Disease",
      "start_date": "2024-03-27",
      "completion_date": "2026-03-31",
      "enrollment": 0,
      "sponsor": "argenx"
    },
    {
      "nct_id": "NCT04598477",
      "title": "A Study to Assess the Long-term Safety and Efficacy of a Subcutaneous Formulation of Efgartigimod PH20 SC in Adults With Pemphigus (Vulgaris or Foliaceus)",
      "status": "TERMINATED",
      "phase": "PHASE3",
      "condition": "Pemphigus Vulgaris, Pemphigus Foliaceus",
      "start_date": "2021-07-15",
      "completion_date": "2024-03-25",
      "enrollment": 0,
      "sponsor": "argenx"
    },
    {
      "nct_id": "NCT03669588",
      "title": "An Efficacy and Safety Study of ARGX-113 in Patients With Myasthenia Gravis Who Have Generalized Muscle Weakness",
      "status": "COMPLETED",
      "phase": "PHASE3",
      "condition": "Generalized Myasthenia Gravis",
      "start_date": "2018-08-22",
      "completion_date": "2020-04-06",
      "enrollment": 0,
      "sponsor": "argenx"
    },
    {
      "nct_id": "NCT03770403",
      "title": "A Safety and Tolerability Study of ARGX-113 in Patients With Myasthenia Gravis Who Have Generalized Muscle Weakness.",
      "status": "COMPLETED",
      "phase": "PHASE3",
      "condition": "Generalized Myasthenia Gravis",
      "start_date": "2019-03-01",
      "completion_date": "2022-06-30",
      "enrollment": 0,
      "sponsor": "argenx"
    },
    {
      "nct_id": "NCT04833894",
      "title": "Evaluating the Pharmacokinetics, Pharmacodynamics, and Safety of Efgartigimod Administered Intravenously in Children With Generalized Myasthenia Gravis",
      "status": "RECRUITING",
      "phase": "PHASE2, PHASE3",
      "condition": "Generalized Myasthenia Gravis",
      "start_date": "2021-10-26",
      "completion_date": "2027-03",
      "enrollment": 0,
      "sponsor": "argenx"
    },
    {
      "nct_id": "NCT07377396",
      "title": "A Study to Assess the Safety of ARGX-124 in Healthy Volunteers",
      "status": "NOT_YET_RECRUITING",
      "phase": "PHASE1",
      "condition": "Healthy Volunteers",
      "start_date": "2026-01-23",
      "completion_date": "2026-12-31",
      "enrollment": 0,
      "sponsor": "argenx"
    },
    {
      "nct_id": "NCT04241549",
      "title": "A Study of Cusatuzumab Plus Azacitidine in Japanese Participants With Newly Diagnosed Acute Myeloid Leukemia or High-risk Myelodysplastic Syndrome Who Are Not Candidates for Intensive Treatment",
      "status": "COMPLETED",
      "phase": "PHASE1",
      "condition": "Leukemia, Myeloid, Acute",
      "start_date": "2020-03-25",
      "completion_date": "2021-07-19",
      "enrollment": 0,
      "sponsor": "OncoVerity, Inc."
    },
    {
      "nct_id": "NCT02965573",
      "title": "A Study to Evaluate the Safety, Efficacy, and Pharmacokinetics of ARGX-113 in Patients With Myasthenia Gravis Who Have Generalized Muscle Weakness",
      "status": "COMPLETED",
      "phase": "PHASE2",
      "condition": "Myasthenia Gravis",
      "start_date": "2016-12-30",
      "completion_date": "2017-10-20",
      "enrollment": 0,
      "sponsor": "argenx"
    },
    {
      "nct_id": "NCT07264426",
      "title": "Real-World Efgartigimod Effectiveness in CIDP: A Prospective Study",
      "status": "RECRUITING",
      "phase": "",
      "condition": "Chronic Inflammatory Demyelinating Polyradiculoneuropathy, CIDP, CIDP (Chronic Inflammatory Demyelinating Polyradiculoneuropathy)",
      "start_date": "2025-08-11",
      "completion_date": "2029-10",
      "enrollment": 0,
      "sponsor": "argenx"
    },
    {
      "nct_id": "NCT01813539",
      "title": "A Study of ARGX-110 in Participants With Advanced Malignancies",
      "status": "COMPLETED",
      "phase": "PHASE1, PHASE2",
      "condition": "Neoplasms",
      "start_date": "2013-02-27",
      "completion_date": "2020-07-10",
      "enrollment": 0,
      "sponsor": "OncoVerity, Inc."
    }
  ],
  "summary": {
    "total_trials": 50,
    "by_phase": {
      "PHASE3": 18,
      "PHASE2, PHASE3": 3,
      "PHASE1": 8,
      "PHASE2": 14,
      "": 4,
      "PHASE1, PHASE2": 2,
      "PHASE4": 1
    },
    "by_status": {
      "ACTIVE_NOT_RECRUITING": 9,
      "TERMINATED": 4,
      "COMPLETED": 20,
      "RECRUITING": 9,
      "NOT_YET_RECRUITING": 3,
      "ENROLLING_BY_INVITATION": 2,
      "APPROVED_FOR_MARKETING": 1,
      "WITHDRAWN": 2
    },
    "active_trials": 20,
    "completed_trials": 20,
    "conditions": [
      "Bioavailability Study",
      "Bullous Pemphigoid",
      "Cancer",
      "Chronic Inflammatory Demyelinating Polyneuropathy (CIDP)",
      "Chronic Inflammatory Demyelinating Polyneuropathy, CIDP, CIDP - Chronic Inflammatory Demyelinating Polyneuropathy",
      "Chronic Inflammatory Demyelinating Polyneuropathy, CIDP, Chronic Inflammatory Demyelinating Polyradiculoneuropathy",
      "Chronic Inflammatory Demyelinating Polyradiculoneuropathy, CIDP, CIDP (Chronic Inflammatory Demyelinating Polyradiculoneuropathy)",
      "Congenital Myasthenic Syndrome",
      "Delayed Graft Function",
      "Dermatomyositis, Myositis",
      "Epidermolysis Bullosa (EB), Epidermolysis Bullosa Acquisita, Recessive Dystrophic Epidermolysis Bullosa, Dystrophic Epidermolysis Bullosa",
      "Generalized Myasthenia Gravis",
      "Generalized Myasthenia Gravis, MG - Myasthenia Gravis, gMG",
      "Generalized Myasthenia Gravis, gMG",
      "Healthy Volunteers",
      "Immune Thrombocytopenia",
      "Immune Thrombocytopenia (ITP), ITP - Immune Thrombocytopenia, ITP, Immune Thrombocytopenic Purpura, Immune Thrombocytopenic Purpura ( ITP ), Idiopathic Thrombocytopenic Purpura, Idiopathic Thrombocytopenic Purpura (ITP)",
      "Leukemia, Myeloid, Acute",
      "Membranous Nephropathy",
      "Multifocal Motor Neuropathy",
      "Multifocal Motor Neuropathy (MMN)",
      "Myasthenia Gravis",
      "Myasthenia Gravis Crisis",
      "Myasthenia Gravis, CIDP - Chronic Inflammatory Demyelinating Polyneuropathy",
      "Myasthenia Gravis, Ocular",
      "Myelodysplastic Syndromes, Leukemia, Myelomonocytic, Chronic",
      "Myositis, Active Idiopathic Inflammatory Myopathy, Dermatomyositis, Polymyositis, Immune-Mediated Necrotizing Myopathy, Antisynthetase Syndrome",
      "Neoplasms",
      "Optic Neuritis",
      "Pemphigus Vulgaris, Pemphigus Foliaceus",
      "Post-COVID Postural Orthostatic Tachycardia Syndrome Postural Orthostatic Tachycardia Syndrome",
      "Postural Orthostatic Tachycardia Syndrome",
      "Primary Immune Thrombocytopenia",
      "Primary Immune Thrombocytopenia (ITP)",
      "Primary Sj\u00f6gren's Syndrome",
      "Thyroid Eye Disease"
    ],
    "lead_stage": "commercial"
  },
  "provenance": {
    "source": "ClinicalTrials.gov API v2",
    "timestamp": "2026-01-29T12:16:34.273252",
    "search_query": "argenx SE",
    "url": "https://clinicaltrials.gov/search?term=argenx+SE"
  }
}